Navigation Links
CRF announces late-breaking trials and first report investigations for TCT 2014
Date:8/1/2014

NEW YORK, NY August 1, 2014 The Cardiovascular Research Foundation (CRF) has announced the late-breaking trials and first report investigations that will be presented at next month's Transcatheter Cardiovascular Therapeutics (TCT) 2014 scientific symposium. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will take place September 13 17, 2014 at the Walter E. Washington Convention Center in Washington, DC.

Clinical research data presented at TCT often direct the course of patient therapies. The studies selected will examine the effectiveness and safety of minimally invasive techniques, pharmaceuticals, technologies, and devices that show potential to treat or prevent cardiovascular disease, one of the leading causes of death globally.

Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Saturday, September 13; Sunday, September 14; Monday, September 15; and Tuesday, September 16.

Media are invited to attend TCT; press credentials and registration information can be found here: http://www.crf.org/tct/press/press-registration-form.

Saturday, September 13

Plenary Session V: Late-Breaking Clinical Trials I
11:00 AM-12:00 PM

PARTNER I: Five-Year Results From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Balloon-Expandable Device Versus Conservative Care in Extremely High-Risk Patients with Aortic Stenosis
Samir R. Kapadia

US CoreValve High Risk Trial: Cost-Effectiveness Analysis From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Self-Expanding Device Versus Surgical Aortic Valve Replacement in High-Risk Patients with Aortic Stenosis
Matthew R. Reynolds

CLEAN-TAVI: A Prospective, Randomized Trial of Cerebral Embolic Protection in High-Risk Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement
Axel Linke

Plenary Session VI: First Reports I
12:00 PM-12:30 PM

The CoreValve US Pivotal Trial: Two-Year Results with a Self-Expanding Bioprosthesis in Extremely High-Risk Patients with Aortic Stenosis
Steven J. Yakubov

ISAR-CLOSURE: A Prospective, Randomized Trial of Two Vascular Closure Devices Versus Manual Compression After Femoral Artery Access
Stefanie Schulz

Sunday, September 14

Plenary Session XII: Late-Breaking Clinical Trials II
11:00 AM-12:00 PM

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease
Patrick W. Serruys

DKCRUSH-VI: A Prospective, Randomized Trial of FFR-Guided Versus Angiography-Guided Provisional T-Stenting in Patients with True Coronary Bifurcation Lesions
Shao Liang Chen

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents
Fernando Alfonso

Plenary Session XII: First Reports II
12:00 PM-12:30 PM

IVUS-CTO: A Prospective, Randomized Trial of Intravascular Ultrasound-Guided Versus Angiography-Guided Drug-Eluting Stent Intervention in Coronary Chronic Total Occlusions
Yang-Soo Jang

OCT STEMI: A Prospective, Randomized Trial of Optical Coherence Tomography Guidance During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction
Pavel Cervinka

Monday, September 15

Plenary Session XIX: Late-Breaking Clinical Trials III
11:10 AM-12:06 PM

BRIGHT: A Prospective, Randomized Trial of Bivalirudin Monotherapy Versus Heparin Monotherapy Versus Heparin Plus Tirofiban in Patients with Acute Myocardial Infarction Undergoing Coronary Intervention
Yaling Han

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation
Nikolaus Sarafoff

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation
Antonio Colombo

Plenary Session XX: First Reports III
12:06 PM-12:36 PM

TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Tracy Y. Wang

VELOCITY: A Prospective, Randomized Trial of Peritoneal Hypothermia in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Gregg W. Stone

Tuesday, September 16

Plenary Session XXVI: Late-Breaking Clinical Trials IV
11:00 AM-12:00 PM

PRIMA: A Prospective, Randomized Trial of PFO Closure in Patients with Refractory Migraine with Aura
David Hildick-Smith

Symplicity Flex: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension
Steffen Desch

EXCITE ISR: A Prospective, Randomized Trial of Excimer Laser Atherectomy Versus Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis
Eric J. Dippel

Plenary Session XXVII: First Reports IV
12:00 PM-12:30 PM

I-LOVE-IT 2: A Prospective, Randomized Trial of a Biodegradable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent Versus a Durable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent in Patients with Coronary Artery Disease
Yaling Han

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease
Stphane Cook


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. AMTC Announces Three Upcoming Audition Sites for Upcoming Performers
2. Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity
3. AAGL Announces It Has Joined With Other Medical Societies to Encourage Hospitals Teaching Endoscopic Surgery to Establish Simulator Labs for Training
4. Quadbase Systems Inc. Announces The Availability Of It’s Flagship Enterprise Reporting, Dashboard and BI Analytics Tool on Amazon’s AWS Marketplace
5. Serious Buyer Announces His Search For Vintage 1960s Grateful Dead Psychedelic Acid Test Concert Posters
6. LDM Global Announces Predictable Simple Fixed-Fee Pricing
7. Addiction Referral Service Live To Be Sober (LiveToBeSober.com) Announces Sponsorship of Jared Blake: Country Music’s Bad Boy, Gone Good
8. BioTechniques: The International Journal of Life Science Methods Announces the Publication of the July 2014 Issue—Available in Print and Online as an Open Access Journal
9. The Beryl Institute Announces Seven New Patient Experience Board Members
10. ReputationChief.Com Announces a New Online Reputation Management Service
11. Ethane Web Technologies Announces Java Development Service at Pocket Friendly Cost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Hotel in New York, NY, on December 3rd, to benefit Holy Name Medical ... the annual event, which raised over $1 million - the largest event in ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... beginning January 1, 2017. The name change aligns the entire company with ... improving health care quality. , “We are very proud of the achievements associated ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , ... Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health Records: A ... Results of the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) ...
(Date:12/8/2016)... ... ... the increasing demand for dental implants, the National Association of Dental Laboratories ( NADL ... about the safety issues related to dental restorations. According to the American Academy of ... reach $6.4 billion in 2018 with more than 30 million Americans missing all their ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching of ... Unified Instance Manager architecture, meeting the needs of multichannel growth and doubling ... unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, administrative ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
(Date:12/8/2016)... global biosurgery market is expected to grow at a ... to 2021. The market is poised to reach USD ... 2016. The market is primarily driven by rising number ... spinal problems, increasing clearance of biosurgery products by regulatory ... In this report, the biosurgery market is ...
(Date:12/8/2016)... Pharmacy, Inc. (NYSE: DPLO) has been recognized by the Detroit ... Standard. To learn more about Diplomat,s career opportunities, visit ... ... ... LLC, a research firm specializing in organizational health and workplace improvement. ...
Breaking Medicine Technology: